Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab
PURPOSE Detection of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) is strongly associated with recurrence risk in early triple-negative breast cancer (TNBC). Prior studies suggest that ctDNA clearance during neoadjuvant therapy (NAT) may predict pathologic complete response (pCR) and enhance the...